Clinical Trial Update: A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 relative bioavailability study of bupropion HCl 150 mg sustained-release tablets under fasting conditions has completed. The trial, sponsored by Sandoz,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Bupropion HCl 150 mg sustained-release tablets (bupropion hydrochloride)

Snippet

Sponsor: Sandoz | Conditions: Depression | Phase 1 | Status: COMPLETED